CINECA IRIS Institutional Research Information System

GRAGNANI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.919
NA - Nord America 2.921
EU - Europa 2.184
SA - Sud America 449
Continente sconosciuto - Info sul continente non disponibili 312
AF - Africa 110
OC - Oceania 2
Totale 9.897
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.804
IT - Italia 1.372
SG - Singapore 1.245
CN - Cina 1.144
HK - Hong Kong 580
BR - Brasile 361
KR - Corea 288
VN - Vietnam 180
IN - India 139
SE - Svezia 130
DE - Germania 115
JP - Giappone 110
GB - Regno Unito 104
FR - Francia 95
CH - Svizzera 78
FI - Finlandia 74
RU - Federazione Russa 64
CA - Canada 47
BD - Bangladesh 38
ZA - Sudafrica 34
IQ - Iraq 32
MX - Messico 32
AR - Argentina 30
TR - Turchia 29
PL - Polonia 28
CI - Costa d'Avorio 26
AT - Austria 24
NL - Olanda 20
SA - Arabia Saudita 20
BG - Bulgaria 15
UA - Ucraina 15
PK - Pakistan 14
VE - Venezuela 13
CZ - Repubblica Ceca 12
UZ - Uzbekistan 12
JO - Giordania 11
CL - Cile 10
CO - Colombia 10
ES - Italia 10
KE - Kenya 10
PH - Filippine 9
MA - Marocco 8
EC - Ecuador 7
IE - Irlanda 7
NP - Nepal 7
TW - Taiwan 7
BB - Barbados 6
EG - Egitto 6
GT - Guatemala 6
ID - Indonesia 6
JM - Giamaica 6
HN - Honduras 5
PS - Palestinian Territory 5
PY - Paraguay 5
TN - Tunisia 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
IL - Israele 4
SN - Senegal 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
AO - Angola 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
GR - Grecia 3
IR - Iran 3
MY - Malesia 3
OM - Oman 3
PE - Perù 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AU - Australia 2
BH - Bahrain 2
BO - Bolivia 2
CG - Congo 2
CR - Costa Rica 2
DK - Danimarca 2
GE - Georgia 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
LY - Libia 2
NG - Nigeria 2
PA - Panama 2
SR - Suriname 2
TJ - Tagikistan 2
AL - Albania 1
AW - Aruba 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BS - Bahamas 1
EE - Estonia 1
EU - Europa 1
GH - Ghana 1
GY - Guiana 1
Totale 9.574
Salva come PNG Salva come JPEG
Città #
Milan 796
Singapore 734
Hong Kong 570
Hefei 476
Santa Clara 440
Ashburn 406
San Jose 376
Seoul 286
Shanghai 245
Boardman 164
Dallas 160
New York 125
Pisa 125
Tokyo 106
Los Angeles 94
Rome 93
Council Bluffs 89
Beijing 82
Bern 72
Hyderabad 63
Fairfield 58
Helsinki 56
Ho Chi Minh City 55
Lauterbourg 55
London 50
Florence 47
Hanoi 43
Seattle 42
Frankfurt am Main 40
Munich 35
Redondo Beach 31
Woodbridge 31
Buffalo 30
Chicago 29
São Paulo 29
Abidjan 26
Warsaw 26
Houston 22
Wilmington 19
Nuremberg 18
Serra 16
Cambridge 15
Chandler 15
Ann Arbor 14
Johannesburg 14
Istanbul 13
Rio de Janeiro 13
Sofia 13
Tashkent 12
Amman 11
Baltimore 11
Turku 11
Chennai 10
Da Nang 10
Elk Grove Village 10
Fuzhou 10
Mexico City 10
Belo Horizonte 9
Brooklyn 9
Cape Town 9
Dhaka 9
Falkenstein 9
San Francisco 9
Baghdad 8
Brno 8
Lucknow 8
Montreal 8
Nairobi 8
Pune 8
Vienna 8
Atlanta 7
Dublin 7
Mumbai 7
Orem 7
Ottawa 7
Phoenix 7
Riyadh 7
Bridgetown 6
Columbus 6
Erbil 6
Guatemala City 6
Hải Dương 6
Lawrence 6
North Bergen 6
Porto Alegre 6
Salt Lake City 6
San Giuliano Terme 6
Zhengzhou 6
Brookline 5
Cairo 5
Dammam 5
Durban 5
Haiphong 5
Jeddah 5
Las Vegas 5
Medford 5
Memphis 5
New Delhi 5
Princeton 5
Santiago 5
Totale 6.737
Salva come PNG Salva come JPEG
Nome #
HBV and HCV testing outcomes among marginalized communities in Italy, 2019–2024: a prospective study 244
B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma 206
Thyroid Autoimmunity and SARS-CoV-2 Infection 155
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 152
IgG cryoglobulinemia 152
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis 146
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 146
COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity 143
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 142
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 142
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 138
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 134
A serum metabolomic analysis of HCV-infected patients successfully treated with IFN-free DAA regimens 131
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups 130
HCV-related rheumatic manifestations and therapeutic strategies 129
Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral sustained viral response (SVR) after antiviral therapy 127
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 127
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 126
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 126
P0752 : NOTCH4 and MHC class II polymorphisms contibute to HCV-related benign and malignant lymphoproliferative diseases 126
Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection 126
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection 125
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study 125
Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients 124
Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26 123
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 123
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 123
Host genetic determinants in HCV-related mixed cryoglobulinemia 121
HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1 121
The Hepatitis C Virus Infection as a Systemic Disease 121
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 121
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 121
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 120
HCV and lymphoproliferation 120
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 119
Detection of WA B Cells in HCV Infection by Molecular Analysis: A Prognostic Marker for Cryoglobulinemic Vasculits and B Cell Lymphomas 118
Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study 117
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 117
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 117
Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection 117
Treatment of HCV-related mixed cryoglobulinemia 117
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 115
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment 114
NOTCH4 AND MHC CLASS II POLYMORPHISMS CONTRIBUTE TO HCV-RELATED BENIGN AND MALIGNANT LYMPHOPROLIFERATIVE DISEASES 113
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 110
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 109
Plasma PAF-AH biological activity decreases in patients with HCV chronic infection 109
HCV infection, malignancy and liver transplantation 108
Non-Invasive B-Cell Clonality Markers May Help in the Rational Approach to HCV Svr Cryoglobulinemic Patients with Persisting Manifestations 107
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 104
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 104
Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series 103
Role of notch receptors in hematologic malignancies 99
HCV AND lymphoma: Genetic and epigenetic factors 93
Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study 90
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 88
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 87
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 81
Assessment of Free Light Chains in HCV positive patients undergoing Rituximab treatment 80
IL28B POLYMORPHISM AS PREDICTOR OF RESPONSE TO ANTI-HCV THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME 79
null 74
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 70
High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy 69
Host genetic determinants in HCV-related mixed cryoglobulinemia 68
Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature 66
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 65
COVID-19 AND CRYOGLOBULINEMIC VASCULITIS. LONG-TERM SURVEY STUDY ON THE IMPACT OF PANDEMIC AND VACCINATION ON A LARGE PATIENT'S POPULATION 63
DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer 63
Evaluation of Plasma miR-17-5p, miR-24-3p and miRNA-223-3p Profile of Hepatitis C Virus-Infected Patients after Treatment with Direct-Acting Antivirals 62
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies 61
Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia 60
Hepatitis C virus lymphotrophism: lessons from a decade of studies 59
Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy 53
Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: Preliminary results of a prospective pilot study 53
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 53
Free light chains: Eclectic multipurpose biomarker 53
Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis 52
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study 52
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 50
Hepatitis b virus-related cryoglobulinemic vasculitis: Review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the italian study group of cryoglobulinemia (gisc) 50
Fibrosis assessment in patients with HCV or HBV chronic infection 46
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 43
Exploratory study of extracellular matrix biomarkers for non-invasive liver fibrosis staging: A machine learning approach with XGBoost and explainable AI 42
KDM2A chromatin regulator constrains senescence program and immunoresponse in liver cancer 42
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life 42
A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders 42
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 41
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 39
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 38
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 38
HIGH SVR RATES WITH SMV plus SOF IN HCV GT1 AND GT4 PATIENTS WITH CIRRHOSIS OR ADVANCED FIBROSIS: A REAL PRACTICE ANALYSIS FROM A LARGE REGIONAL DATABASE IN TUSCANY, ITALY 37
Regression of T(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 37
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 36
Early decrease of T-bet+ B cells during subcutaneous belimumab predicts response to therapy in systemic lupus erythematosus patients 35
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 33
PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases 32
The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis 31
Presence of BCL-2 rearranged B-cell clones in chronic HCV infection may negatively influence virological response to treatment 30
HCV-related cryoglobulinemic vasculitis (mixed cryoglobulinemia syndrome) in the era of direct-acting antivirals: A 10-year experience from Italian tertiary referral centers 29
Il polimorfismo dell'interleuchina 28B come predittore di risposta in pazienti con crioglobulinemia mista HCV-correlata 29
Totale 9.289
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.057
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.057
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202275 0 1 5 4 8 15 1 6 2 12 5 16
2022/2023449 8 6 10 4 4 11 257 19 87 11 23 9
2023/20241.613 277 230 325 178 248 134 20 26 5 22 12 136
2024/20253.658 126 134 40 122 323 238 249 120 304 322 548 1.132
2025/20263.537 248 608 304 306 410 231 557 157 249 246 95 126
2026/2027328 128 200 0 0 0 0 0 0 0 0 0 0
Totale 9.897